Caldera Secures $112.5 Million for CLD-423 Development

Caldera raises significant capital to advance bispecific antibody CLD-423 for treating IBD and inflammatory diseases.

AI-assisted, human-published

Latest headlines

Join us for funding and investment opportunities.

Stay connected!

If you have a serious, bonafide inquiry into the VentureCapital.com or PrivateEquity.com domain names, please contact us here